comparemela.com

Yelena Y. Janjigian, MD, discusses results from the primary progression-free survival and interim overall survival analyses of the phase 3 KEYNOTE-811 trial in patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, and contextualizes these findings with previously reported data from this trial.

Related Keywords

Yelenay Janjigian , ,Gastrointestinal Oncology Service ,Memorial Sloan Kettering Cancer Center ,D ,Keynote 811 Trial ,Nct03615326 ,Patients With Her2 Positive Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.